Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg

Exclusion Criteria

• •Subject has hypersensitivity reaction or clinically significant history about carvedilol or investigator drug.
• •Clinically significant cardiovascular system, respiratory system, liver, kidney, endocrine system, gastrointestinal system, central nervous system, blood tumor, mental disease, skin disease, otorhinolaryngologic diseases and so on.
• •Hypotension(SBP \< 105mmHg or DBP \< 65mmHg), Hypertension(SBP \> 150mmHg or DBP \> 100mmHg)
• •Heart rate \< 50times/minute
• •Active liver disease or AST, ALT \> 1.5\*upper limit of normal range
• •Creatinine clearance \< 80mL/min
• •Subject has a disease affecting drug's ADME or gastrointestinal surgery.
• •Subject with symptoms of injured or acute disease within 28days before the first IP administration.
• •Subject has a history of drug abuse or a positive reaction for drug abuse at the screening test for urine.
• •Taking ETC medicine including oriental medicine within 14days before the first IP administration or Taking OTC medicine within 7days
• •Subject takes an abnormal meal which affect the ADME of drug.
• •Previously participate in other trial within 90days.
• •Previously make whole blood donation within 60days or component blood donation within 30days before the first IP administration.
• •Continued to be taking caffeine(caffeine \> 5cup/day), drinking(alcohol \> 21unit/week, 1unit = 10g = 12.5mL of pure alcohol) or during clinical trials can not be drunk or severe heavy smoker(cigarette \> 10cigarettes/day).
• •Subject with positive reaction about serum test(HBsAg, HCV Ab, HIV Ag/Ab, VDRL)
• •Genetic problems such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption.
• •An impossible one who participates in clinical trial by investigator's decision including for reason of laboratory test result.